Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia

[1]  L. Churilov,et al.  Evolution of eligibility criteria for diffuse large B‐cell lymphoma randomised controlled trials over 30 years , 2021, British journal of haematology.

[2]  Ruishan Liu,et al.  Evaluating eligibility criteria of oncology trials using real-world data and AI , 2021, Nature.

[3]  E. Eisenhauer,et al.  Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. , 2021, JAMA oncology.

[4]  B. Giantonio.  Eligibility in Cancer Clinical Research: The Intersection of Discovery, Generalizability, Beneficence, and Justice , 2021, Clinical Cancer Research.

[5]  Edward S. Kim,et al.  Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement , 2021, Clinical Cancer Research.

[6]  Edward S. Kim,et al.  Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations , 2021, Clinical Cancer Research.

[7]  J. Cerhan,et al.  Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind? , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Sorror,et al.  Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility , 2020, Haematologica.

[9]  N. Charness,et al.  Clinical Trial Generalizability Assessment in the Big Data Era: A Review , 2020, Clinical and translational science.

[10]  B. Stevens,et al.  Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. , 2019, Blood advances.

[11]  J. Unger,et al.  Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation , 2019, JAMA oncology.

[12]  Dawn L Hershman,et al.  Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation , 2019, Journal of the National Cancer Institute.

[13]  J. Radich,et al.  Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. , 2018, Blood.

[14]  Edward S. Kim,et al.  Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Caroline Schenkel,et al.  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Xian-Jin Xie,et al.  Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  M. Sekeres,et al.  The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies , 2017, Leukemia.

[18]  E. Estey,et al.  A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study , 2017, Leukemia & lymphoma.

[19]  F. Vera-Badillo,et al.  Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies. , 2016, Cancer treatment reviews.

[20]  Keith Humphreys,et al.  Representativeness of patients enrolled in influential clinical trials: a comparison of substance dependence with other medical disorders. , 2013, Journal of studies on alcohol and drugs.

[21]  Keith Humphreys,et al.  Extent and reporting of patient nonenrollment in influential randomized clinical trials, 2002 to 2010. , 2013, JAMA internal medicine.

[22]  D. Cescon,et al.  Presentation of nonfinal results of randomized controlled trials at major oncology meetings. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Kiss,et al.  Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. , 2007, JAMA.

[24]  C. Gross,et al.  Reporting the Recruitment Process in Clinical Trials: Who Are These Patients and How Did They Get There? , 2002, Annals of Internal Medicine.